Dark

TBPH
Theravance Biopharma, Inc.
stock NASDAQ

At Close

Sep 11, 2026 3:59:56 PM EDT

17.02USD0.000%(0.00)420,492

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-17.02)0

After-hours

Sep 10, 2026 4:00:30 PM EDT

17.02USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

06:07AM EST Theravance Biopharma Enrolls First Patient In Phase 4 Study Of YUPELRI Inhalation Solution RTTNews

06:01AM EST Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI Phase 4 Study Benzinga

06:01AM EST Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI(r) PR Newswire

Jan 5, 2022

06:01AM EST Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare PR Newswire

Nov 18, 2021

06:01AM EST Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire

Nov 16, 2021

06:21AM EST Theravance Biopharma Announced in 8K Filing That It Has Voluntarily Discontinued Its Phase 2 Study of Izencitinib in Crohn's Disease Due to Concerns About the Ongoing Benefit-risk of Continuing the Trial Benzinga

Nov 5, 2021

12:12PM EDT Expert Ratings For Theravance Biopharma Benzinga

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 Benzinga

09:36AM EDT A Peek Into The Markets: US Stock Futures Mixed; All Eyes On Jobs Report Benzinga

09:36AM EDT JP Morgan Upgrades Theravance Biopharma to Neutral, Raises Price Target to $12 Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

Nov 3, 2021

05:49PM EDT Theravance Biopharma Q3 Adj. EPS $(0.46) Beats $(0.55) Estimate, Sales $13.19M Miss $14.69M Estimate Benzinga

04:06PM EDT Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and PR Newswire

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Oct 20, 2021

06:01AM EDT Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, PR Newswire

Sep 21, 2021

10:26AM EDT Theravance Biopharma Granted U.S. Patent Titled 'Neprilysin inhibitors' Benzinga

Sep 16, 2021

01:25PM EDT Analyst Ratings For Theravance Biopharma Benzinga

07:58AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

07:48AM EDT The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study Benzinga

07:47AM EDT Morgan Stanley Maintains Underweight on Theravance Biopharma, Lowers Price Target to $10 Benzinga

06:38AM EDT HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $8 Benzinga

06:37AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $10 Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

06:09AM EDT Theravance Biopharma Announces Strategic Actions; Says Headcount Will Be Reduced By About 75% RTTNews

06:09AM EDT Theravance Biopharma, Inc. Announces Strategic Actions To Focus On Respiratory Disease Portfolio Benzinga

06:08AM EDT Theravance Biopharma Says Phase 3 Study Of Ampreloxetine Did Not Meet Primary Endpoint RTTNews

06:07AM EDT Theravance Biopharma Reports Results From A Phase 3 Study Of Ampreloxetine In Patients With Symptomatic Neurogenic Orthostatic Hypotension; Co. Reported 'The study did not meet its primary endpoint' Benzinga

06:06AM EDT Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory PR Newswire

06:05AM EDT Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of PR Newswire

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 26, 2021

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

Aug 25, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2021 Benzinga

07:50AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

06:05AM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide Benzinga

06:05AM EDT Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates Benzinga

04:45AM EDT Morgan Stanley Downgrades Theravance Biopharma to Underweight, Lowers Price Target to $14 Benzinga

Aug 24, 2021

02:45PM EDT Mid-Afternoon Market Update: Nasdaq Rises 75 Points; Palo Alto Networks Shares Jump On Upbeat Earnings Benzinga

12:18PM EDT What 10 Analyst Ratings Have To Say About Theravance Biopharma Benzinga

12:18PM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide Benzinga

10:15AM EDT Shares of Theravance Biopharma Inc. (TBPH) are currently down over 30% after its ulcerative colitis drug trial failed to meet primary goals. RTTNews

10:13AM EDT Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2021 Benzinga

08:31AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

07:03AM EDT Cowen & Co. Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $14 Benzinga

06:47AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $29 Benzinga

06:13AM EDT Needham Maintains Buy on Theravance Biopharma, Lowers Price Target to $18 Benzinga

06:11AM EDT HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $21 Benzinga

05:57AM EDT The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.45 A.M. EDT). RTTNews

Aug 23, 2021

05:05PM EDT Shares of Theravance Biopharma, Inc. (TBPH) tanked over 20% in extended trading session on Monday after the biopharmaceutical company said that a dose-finding study of its drug izencitinib failed to meet primary endpoint. RTTNews

04:09PM EDT Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis; Co. Reports 'Randomized, double-blind, placebo-controlled study did not meet the primary endpoint' Benzinga

04:06PM EDT Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis PR Newswire

Aug 4, 2021

06:52AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $37 Benzinga

Aug 3, 2021

04:51PM EDT Recap: Theravance Biopharma Q2 Earnings Benzinga

04:01PM EDT Theravance Biopharma Q2 EPS $(0.80) Beats $(1.01) Estimate, Sales $12.91M Miss $15.41M Estimate Benzinga

04:00PM EDT Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and PR Newswire

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

06:01AM EDT Theravance Biopharma to Report Second Quarter 2021 Financial Results on August PR Newswire

Jul 16, 2021

09:11AM EDT Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $27 Benzinga

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 28, 2021

06:31AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $36 Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

04:19AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 4.30 A.M.) RTTNews

Jun 24, 2021

10:59PM EDT Theravance Biopharma Prices Public Offering Of 6.70 Mln Shares At $15.00/shr RTTNews

10:57PM EDT Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary PR Newswire

05:22PM EDT Shares of Theravance Biopharma, Inc. (TBPH) slipped nearly 10% in extended trading session on Thursday after the company announced proposed public offering of ordinary shares. RTTNews

04:34PM EDT Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares; No Terms Disclosed Benzinga

04:34PM EDT Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares PR Newswire

Jun 21, 2021

07:37AM EDT Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study Benzinga

06:32AM EDT Theravance Biopharma, Inc. (TBPH), a biopharmaceutical company primarily focused on organ-selective medicines, announced Monday that its Phase 2 study of 3 mg once-daily nezulcitinib did not meet the primary endpoint. RTTNews

06:08AM EDT Theravance Biopharma Says Phase 2 Study Of Nezulcitinib Fails To Meet Primary Endpoint RTTNews

06:07AM EDT Theravance Biopharma, Inc. Announces Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19; Co. Reports 'Randomized, double-blind, placebo-controlled study did not meet the primary endpoint' Benzinga

06:05AM EDT Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 PR Newswire

May 13, 2021

11:36AM EDT Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $28 Benzinga

May 6, 2021

06:01AM EDT Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire

May 5, 2021

07:38AM EDT Needham Maintains Buy on Theravance Biopharma, Lowers Price Target to $32 Benzinga

07:10AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $39 Benzinga

May 4, 2021

04:51PM EDT Theravance Biopharma: Q1 Earnings Insights Benzinga

04:38PM EDT Theravance Biopharma Sees FY21 R&D Expense $195M-$225M Benzinga

04:38PM EDT Theravance Biopharma Q1 EPS $(1.24) Misses $(1.05) Estimate, Sales $14.30M Miss $17.27M Estimate Benzinga

04:06PM EDT Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and PR Newswire

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 20, 2021

06:01AM EDT Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, PR Newswire

Apr 1, 2021

06:55AM EDT SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $40 Benzinga

Mar 2, 2021

06:01AM EST Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire

Mar 1, 2021

09:33AM EST Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $30 Benzinga

Feb 24, 2021

07:13AM EST SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $41 Benzinga

Feb 23, 2021

04:45PM EST Theravance Biopharma: Q4 Earnings Insights Benzinga

04:21PM EST Theravance Biopharma Sees Operating Expenses For R&D At $195M-$225M Benzinga

04:20PM EST Theravance Biopharma Q4 EPS $(0.92) Beats $(1.02) Estimate, Sales $18.73M Miss $20.85M Estimate Benzinga

04:06PM EST Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial PR Newswire

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 22, 2021

10:16AM EST Theravance Biopharma Earnings Preview Benzinga

Feb 10, 2021

06:01AM EST Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire

Feb 9, 2021

06:01AM EST Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial PR Newswire

Jan 5, 2021

06:01AM EST Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 16, 2020

01:15PM EST Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $31 Benzinga

Nov 24, 2020

09:11AM EST Evercore ISI Group Reinstates Outperform on Theravance Biopharma, Announces $30 Price Target Benzinga

Nov 17, 2020

06:01AM EST Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx PR Newswire

Nov 6, 2020

08:19AM EST 10 Biggest Price Target Changes For Friday Benzinga

07:51AM EST SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $35 Benzinga

Nov 5, 2020

04:57PM EST Theravance Biopharma Sees FY 2020 Operating Loss Between $(225M) And $(235M) Benzinga

04:56PM EST Theravance Biopharma Q3 EPS $(1.16) Misses $(0.97) Estimate, Sales $18.30M Miss $18.58M Estimate Benzinga

04:06PM EST Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and PR Newswire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 22, 2020

06:01AM EDT Theravance Biopharma to Report Third Quarter 2020 Financial Results on November PR Newswire

Oct 14, 2020

10:01AM EDT Benzinga's Top Upgrades, Downgrades For October 14, 2020 Benzinga

05:02AM EDT Morgan Stanley Upgrades Theravance Biopharma to Overweight Benzinga

Sep 1, 2020

06:01AM EDT Theravance Biopharma to Present at Upcoming Investor Conferences PR Newswire

Aug 10, 2020

10:37AM EDT Piper Sandler Maintains Overweight on Theravance Biopharma, Lowers Price Target to $30 Benzinga

09:31AM EDT Morgan Stanley Maintains Equal-Weight on Theravance Biopharma, Lowers Price Target to $29 Benzinga

Aug 6, 2020

05:43PM EDT Theravance Biopharma Q2 EPS $(1.00) Misses $0.98 Estimate, Sales $15.01M Miss $19.64M Estimate Benzinga

04:35PM EDT Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and PR Newswire

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Jul 27, 2020

06:01AM EDT Theravance Biopharma to Report Second Quarter 2020 Financial Results on August PR Newswire